Highest-materiality recent filing
Jade Biosciences prices $150M public offering of 10M shares at $15/share
Priced public offering of 10,000,000 shares of common stock at $15.00 per share for gross proceeds of $150.0M.
Mean IgA reduction ~70% from baseline, sustained at 12 weeks with single 700 mg dose; steady-state simulation supports Q12W dosing.
Jade Biosciences Q1 net loss $40.4M, cash $311.3M; pipeline and CMO appointment
Net loss $40.4M for Q1 2026 vs $38.2M in Q1 2025, driven by higher R&D and G&A costs.
Andrew King promoted to President, R&D at Jade Biosciences
Andrew King previously CSO and Head of R&D appointed President Research & Development effective April 18 2026
Jade Biosciences approves 2026 Inducement Plan, reserving 1.75M shares for new hires
Board approved 2026 Employment Inducement Stock Incentive Plan, effective March 31, 2026.
Jade Biosciences reports $336M cash; JADE101 Phase 1 data expected Q2 2026
Cash, equivalents, and investments of $336.2M as of Dec 31, 2025; runway into first half 2028.
Jade Biosciences reports $336M cash; outlines 2026 pipeline milestones including JADE101 Phase 2
Cash, cash equivalents and investments ~$336M as of Dec 31, 2025; funds operations into H1 2028.
Jade Biosciences raises $45M in private placement with BB Biotech at $14/share
Private placement of 3,214,286 shares at $14.00 per share for gross proceeds of ~$45M.
Jade Biosciences Q3 net loss $25.2M; cash runway into H1 2028 after $135M placement
Q3 2025 net loss of $25.2M vs $16.3M loss in Q3 2024; R&D expenses $22.0M, G&A $5.4M.
Jade Biosciences raises $135M in PIPE; unveils BAFF-R candidate JADE201
Private placement raises ~$135M gross via 13.37M shares at $9.14 and pre-funded warrants; close expected Oct 8, 2025.
Chief Medical Officer Hetal Kocinsky departs; Andrew King to lead clinical programs
Hetal Kocinsky, M.D., left CMO role effective Sept 9, 2025.
Jade Biosciences Q2 net loss $32.1M; cash $220.9M; JADE101 Phase 1 starts Q3
Net loss of $32.1M for Q2 2025; R&D expense $22.5M, G&A $5.2M; non-cash stock comp $4.0M.
Jade Biosciences appoints Brad Dahms as CFO, enters manufacturing agreement with Patheon for JADE101
Brad Dahms appointed CFO effective July 14, 2025; base salary $500K, target bonus 40%, option for 526,000 shares vesting over 4 years.
Jade Biosciences Q1 2025 net loss $38.2M, cash $49.9M, merger closed Apr 28
Net loss of $38.2M for Q1 2025; R&D expenses $20.0M, G&A $3.4M; change in fair value of convertible notes added $15.4M to other expense.
Jade Biosciences completes reverse merger with Aerovate; former Aerovate holders own ~1.4%
Merger closed April 28, 2025; Aerovate stockholders received ~$69.6M special dividend ($2.40 pre-split) and ~1.4% of combined entity.
Jade Biosciences provides updated corporate presentation; no material new details disclosed
Company changed name from Aerovate Therapeutics to Jade Biosciences, effective prior to this filing; trades under ticker JBIO on Nasdaq.
Aerovate moves special dividend payment to April 28, contingent on merger close
Special cash dividend of $2.40/share ($69.6M aggregate) record date April 25, payment moved to April 28.
Aerovate stockholders approve merger with Jade Biosciences, 1-for-35 reverse split
All eight proposals approved at April 16 special meeting, including merger and reverse stock split.
Aerovate discloses stockholder lawsuits and demand letters over merger with Jade Biosciences
Two lawsuits filed March 27, 2025 in NY state court alleging misrepresentations in S-4; seek injunctive relief or damages.
Special cash dividend of $69.6M ($2.40/share) declared, payable to holders of record as of April 25, 2025.
Aerovate announces $67.6-69.6M cash dividend range for proposed merger; stockholder vote April 16
Cash dividend expected $67.6-69.6M in aggregate, based on estimated net cash prior to merger closing.
Aerovate to merge with Jade Biosciences; Jade holders to own 98.4%
Aerovate (AVTE) reverse-merges with Jade; pre-merger Jade stockholders receive 98.4% of combined firm; Aerovate holders receive 1.6%.
Aerovate regains Nasdaq audit committee compliance by appointing Habib J. Dable
Company notified Nasdaq of noncompliance on Oct 11 due to only two audit committee members after Dr. Katabi's resignation.
Director Maha Katabi resigns from Aerovate board and committees effective Oct 6, 2024
Maha Katabi, Ph.D., resigned from the board, Audit Committee, and Compensation Committee.
Aerovate Therapeutics halts Phase 3 PAH trial, launches strategic alternatives review with Wedbush
Previously halted enrollment and shut down Phase 3 IMPAHCT trial and long-term extension study.
Aerovate Therapeutics to reduce nearly all workforce after ending AV-101 trial
On June 25, 2024, Aerovate began workforce reduction after ending AV-101 clinical program.
Aerovate Therapeutics cuts 78% of workforce after halting AV-101 trial
Reduction follows shutdown of Phase 2b/3 trial of AV-101 and long-term extension study.
Aerovate Phase 2b trial of AV-101 fails primary endpoint; halts Phase 3 and extension
AV-101 did not meet primary endpoint of PVR improvement at any dose (10, 35, 70 mg BID); p-values all >0.36.
Aerovate Therapeutics stockholders elect directors and ratify KPMG as auditor at 2024 annual meeting
Stockholders elected David Grayzel, M.D. and Maha Katabi, Ph.D. as Class III directors with 24.4M and 25.9M votes for, respectively.
Aerovate reports Q1 2024 net loss $23.2M; cash $99.3M; Phase 2b topline data expected June 2024
Net loss of $23.2M for Q1 2024 vs $16.5M in Q1 2023; R&D expenses $20.1M, G&A $4.5M.
Aerovate Therapeutics furnishes corporate presentation; no material news disclosed
Filed under Item 7.01 as Regulation FD disclosure; presentation used for investor meetings starting March 27, 2024.
Aerovate reports 2023 net loss $75.5M; Phase 2b topline data for AV-101 in PAH expected June 2024
Cash, cash equivalents and short-term investments totaled $122.4M at Dec 31, 2023; cash runway expected into 2026.
On October 6, 2024, Maha Katabi, Ph.D., provided notice of her resignation from the board of directors (the “Board”) of Aerovate Therapeutics, Inc. (the “Company”), effective as of October 6, 2024.
Max materiality 1.00 · Median 0.68 · Most common event other_material